Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Vimian Group AB ( (SE:VIMIAN) ) is now available.
Vimian Group AB reported broad-based growth in 2025, expanding its MedTech dental platform while working to mitigate headwinds in its MedTech orthopedics business. The company delivered 13% total revenue growth, 6% organic growth and 11% adjusted EBITA growth, achieving a 24.8% adjusted EBITA margin, supported by strong operational cash generation and a completed listing transfer to the Nasdaq Main Market, which strengthens its market profile and access to capital.
These results underscore Vimian’s resilience and strategic focus on higher-growth niches within animal health, particularly in dental MedTech, even as it navigates challenges in orthopedics. The combination of solid profitability, robust cash flow and an upgraded stock market listing reinforces its positioning as a consolidator in the animal health technology space and provides a stronger platform for future expansion and stakeholder confidence.
The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK29.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian Group AB operates in the animal health sector, focusing on improving animal well-being through science and technology. The group is active in veterinary MedTech, including dental and orthopedic solutions, and targets broad-based growth across its specialized platforms.
Average Trading Volume: 257,224
Technical Sentiment Signal: Sell
Current Market Cap: SEK13.83B
Find detailed analytics on VIMIAN stock on TipRanks’ Stock Analysis page.